{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}],"title":"At least one TEAE of peripheral neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"}]}],"title":"Neuropathy peripheral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"Peripheral sensory neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Neuralgia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Peripheral motor neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Polyneuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Sensory disturbance"}],"denoms":[{"counts":[{"groupId":"OG000","value":"587"}],"units":"Participants"}],"description":"Number of participants with at least one peripheral neuropathy treatment-emergent adverse event (TEAE), and number of participants reporting AEs coded to preferred terms that comprise the search terms for peripheral neuropathy in MedDRA version 9.0 are listed. A participant with multiple occurrences of a TEAE was counted only once for that category.","groups":[{"description":"Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.","id":"OG000","title":"Lenalidomide Plus Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"up to 124 weeks","title":"Participants With Adverse Events of Special Interest: Peripheral Neuropathy","type":"SECONDARY","unitOfMeasure":"participants"}